Table 3 Patient characteristics according to mismatch repair status.
pMMR | dMMR | Not tested | Total | p-value* | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
585 | 76% | 58 | 8% | 122 | 16% | 765 | 100% | |||
Median age (range) | 71 (30–99) | 74 (36–95) | 75 (28–96) | 72 (28–99) | 0.012 | |||||
Total | 585 | 100% | 58 | 100% | 122 | 100% | 765 | 100% | ||
Age groups | ≤70 years | 258 | 44% | 18 | 31% | 37 | 30% | 313 | 41% | 0.055 |
>70 years | 327 | 56% | 40 | 69% | 85 | 70% | 452 | 59% | ||
Sex | Male | 321 | 55% | 16 | 28% | 68 | 56% | 405 | 53% | <0.001 |
Female | 264 | 45% | 42 | 72% | 54 | 44% | 360 | 47% | ||
Primary tumour | Right colon | 199 | 34% | 48 | 83% | 44 | 37% | 291 | 38% | <0.001 |
location | Left colon | 159 | 27% | 7 | 12% | 41 | 34% | 207 | 27% | |
Rectum | 225 | 39% | 3 | 5% | 34 | 29% | 262 | 34% | ||
Unknown/multiple | 2 | – | – | – | 3 | – | 5 | – | – | |
Primary resection | No | 232 | 40% | 14 | 24% | 93 | 76% | 339 | 44% | 0.02 |
Yes | 353 | 60% | 44 | 76% | 29 | 24% | 426 | 56% | ||
Tumour grade | Low | 396 | 74% | 14 | 25% | 57 | 63% | 467 | 68% | <0.001 |
High | 140 | 26% | 43 | 75% | 33 | 37% | 216 | 32% | ||
Missing | 49 | – | – | – | 32 | – | 82 | – | – | |
Presentation of metastases | Synchronous | 380 | 65% | 31 | 53% | 99 | 81% | 510 | 67% | 0.082 |
Metachronous | 205 | 35% | 27 | 47% | 23 | 19% | 255 | 33% | ||
Number of metastatic sites | 1 | 281 | 48% | 31 | 53% | 55 | 45% | 367 | 48% | 0.712 |
2 | 210 | 36% | 18 | 31% | 45 | 37% | 273 | 36% | ||
3–5 | 94 | 16% | 9 | 16% | 22 | 18% | 125 | 16% | ||
Metastatic sites | Liver | 378 | 65% | 30 | 52% | 90 | 74% | 498 | 65% | 0.052 |
Lung | 241 | 41% | 16 | 28% | 48 | 39% | 305 | 40% | 0.044 | |
Peritoneum | 152 | 26% | 24 | 41% | 30 | 25% | 206 | 27% | 0.012 | |
Lymph nodes | 143 | 24% | 17 | 29% | 36 | 30% | 196 | 26% | 0.414 | |
Bone | 22 | 4% | 2 | 3% | 6 | 5% | 30 | 4% | 1.000 | |
Brain | 12 | 2% | 1 | 2% | 3 | 2% | 16 | 2% | 1.000 | |
Other | 64 | 11% | 6 | 10% | 10 | 8% | 80 | 10% | 0.890 | |
ECOG PS | 0 | 220 | 38% | 15 | 26% | 17 | 14% | 252 | 33% | 0.017 |
1 | 189 | 32% | 15 | 26% | 39 | 32% | 243 | 32% | ||
2–4 | 176 | 30% | 28 | 48% | 65 | 54% | 269 | 35% | ||
Not available | – | – | – | – | 1 | – | 1 | – | – | |
Mutation status | BRAF-V600Emt | 78 | 14% | 34 | 59% | 11 | 15% | 123 | 17% | <0.001 |
RASmt | 320 | 55% | 9 | 16% | 36 | 49% | 365 | 52% | ||
RAS&BRAFwt | 179 | 31% | 15 | 26% | 26 | 36% | 220 | 31% | ||
Not tested | 8 | – | – | – | 49 | – | 57 | – | – | |
Type of treatment | Metastasectomy | 193 | 33% | 10 | 17% | 10 | 8% | 213 | 28% | <0.001 |
Systemic therapy only | 261 | 45% | 21 | 36% | 52 | 43% | 334 | 44% | ||
Best supportive care | 131 | 22% | 27 | 47% | 59 | 49% | 217 | 28% | ||
Not known | – | – | – | – | 1 | – | 1 | – | – | |
